This needs a lot more looking in to, but it suggests that psoriasis patients using bio's have a low risk of ending up in hospital due to covid.

Quote:

---

Background:
The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited.

Objective:
Characterize the course of COVID-19 in psoriasis and identify factors associated with hospitalization.

Methods:
Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an international registry, PsoProtect. Multiple logistic regression assessed the association between clinical/demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviours.

Results:
Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24-8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% CI 1.31-6.18). No significant differences were found between biologic classes. Independent patient-reported data (n=1,626 across 48 countries) suggested lower levels of social isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 0.68, 95% CI 0.50-0.94).

Conclusion:
In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, comorbidities) were associated with higher hospitalization rates.

Clinical Implications:
We identify risk factors for COVID-19-related hospitalization in psoriasis patients, including older age, male sex, non-white ethnicity and comorbidities. Use of biologics was associated with lower hospitalization risk than non-biologic systemic therapies.

Source: jacionline.org

*Funding: We acknowledge financial support from the Department of Health via the National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London; The Psoriasis Association; NIHR Manchester Biomedical Research Centre. SKM is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership award (MR/T02383X/1). ND is funded by Health Data Research UK (MR/S003126/1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; and Wellcome. ZZNY is funded by a National Institute for Health Research (NIHR) Academic Clinical Lectureship through the University of Manchester. CEMG is a NIHR Emeritus Senior Investigator and is funded in part by the MRC (MR/101 1808/1). CEMG and RBW are in part supported by the NIHR Manchester Biomedical Research Centre. SML is supported by a Wellcome senior research fellowship in clinical science (205039/Z/16/Z). SML is also supported by Health Data Research UK (grant no. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust.

Biological Treatments For Psoriasis

That's very interesting and great news for psoriasis sufferers who are on biologicals.
I think they have been trialing bios as a treatment for covid and have had some success

Let's hope this is a bonus for psoriasis sufferers on biologicals

I know Psoprotect !!

There are even two versions, you have Psoprotect for the professionals, dermatologists etc and you have Psoprotectme where the patients themselves can report their issues/side-effects, etc.

Indeed we had already discussed somewhere in the covid thread that it might be possible that our biologicals might protect against Covid as bio's block certain cytokines and Covid is known for the so called cytokine storm.
Would be very interesting to dig deeper in this stuff.
For now the research is not very broad yet.

@Jim, remember that DMF also moderates several cytokines to a lower level...

@Caroline yes I was thinking the same about DMF and hope I get some protection as it does a similar job to the bios

There is investigation of DMF as a covid treatment being conducted currently. It may be able to inhibit replication of the virus.

(Wed-28-10-2020, 11:24 AM)Bill Wrote: There is investigation of DMF as a covid treatment being conducted currently. It may be able to inhibit replication of the virus.

Let's hope the study gets positive results Bill. It would be a win win situation for us if it's found to inhibit the virus 

(Wed-28-10-2020, 12:30 PM)jiml Wrote:

(Wed-28-10-2020, 11:24 AM)Bill Wrote: There is investigation of DMF as a covid treatment being conducted currently. It may be able to inhibit replication of the virus.

Let's hope the study gets positive results Bill. It would be a win win situation for us if it's found to inhibit the virus 

That would be very great and another example of the vast possibilities of DMF.

(Wed-28-10-2020, 19:21 PM)Caroline Wrote:

(Wed-28-10-2020, 12:30 PM)jiml Wrote:

(Wed-28-10-2020, 11:24 AM)Bill Wrote: There is investigation of DMF as a covid treatment being conducted currently. It may be able to inhibit replication of the virus.

Let's hope the study gets positive results Bill. It would be a win win situation for us if it's found to inhibit the virus 

That would be very great and another example of the vast possibilities of DMF.

The paper that I read regarding the biological drugs and Covid related to IL6 which is a cause of types of arthritis.I am not sure exactly what the conclusion of the article came to regarding risk for psoriasis patients against people without psoriasis or was it just a comparison of psoriasis patients just having different types of treatment.

Had COVID for 10 days, cough, fever and fatigue.  Doing much better now. 

Just a FYI- my psoriasis exploded while infected.  My skin erupted with scales in places I've never had any issues.  Skin has calmed down and back to "normal".

Another side effect, my arthritis has improved, now taking 2/3 my normal pain meds.

COVID is a strange disease, and very transmissible.


Mike